Skip to content

A clinical study to evaluate Micellar Iron for treatment of Iron Deficiency Anaemia

Evaluation of efficacy and safety of Micellar Iron in the treatment of Iron Deficiency Anaemia patients: A prospective, randomised, double-blind, single centre, placebo-controlled, interventional study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/12/029778
Enrollment
70
Registered
2020-12-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D509- Iron deficiency anemia, unspecified

Interventions

Intervention1: Micellar Iron Sachets: The investigational product, Micellar Iron is a nutraceutical product, formulated as an edible powder which has Micellar Iron (Ferrous Bisglycinate), vitamin C, B

Sponsors

Amitojas Wellness Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male and female subjects aged 18 years and above. 2. Male subjects with haemoglobin level below 13.0 g/dL and female subjects with haemoglobin level below 12.0 g/dL. 3. Subjects willing to provide informed written consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant, planning to become pregnant or breastfeeding women. 2. Subjects with anaemia other than iron deficiency anaemia. 3. Subjects have undergone blood transfusion or underwent iron therapy in the last three months. 4. Subjects with microcytic iron-overloading disorder (thalassemia, sideroblastic anemia) 5. Current or past history of a serious illness including, seizures, major psychiatric illness, structural brain disease, liver or kidney failure, organ transplantation, rheumatoid arthritis, uncontrolled hypertension, uncontrolled diabetes or malignancy, cardiovascular event in the last three months. 6. Alcohol or substance abuse 7. Allergy or sensitivity to any of the ingredients in the study treatment 8. Subjects who have participated in other clinical studies during the past 3 months or subjects who intend to participate in other clinical studies parallelly 9. Subjects with any other illness or health condition which in the opinion/medical judgement of the study investigator makes the subject ineligible to participate in the study.

Design outcomes

Primary

MeasureTime frame
Serum Ferritin levels documented in the CRF at baseline, and day 30 (values and change from baseline - within the group and between the groups comparisons)Timepoint: baseline and day 30

Secondary

MeasureTime frame
Haemoglobin levels documented in the CRF at baseline, and day 30 (values and change from baseline - within the group and between the groups comparisons)Timepoint: baseline and day 30

Countries

India

Contacts

Public ContactMr Kamal Kammili

Amitojas Wellness Private Limited

cso@amitojas.com8885324455

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026